Bioptik Technology (4161) — Capital Reinvestment Ratio
Bioptik Technology (4161) has a Capital Reinvestment Ratio of 0.09x as of December 2025, meaning it reinvests 0% of its operating cash flow (NT$53.21 Million) in capital expenditures (NT$4.94 Million). See 4161 equity financing ratio to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Bioptik Technology Capital Reinvestment Ratio (2017–2025)
This chart tracks Bioptik Technology's Capital Reinvestment Ratio across 8 annual periods. Check total reinvestment intensity of Bioptik Technology to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Bioptik Technology (2017–2025)
Year-by-year Capital Reinvestment Ratio for Bioptik Technology from 2017 to 2025. For live market cap and broader valuation context, see 4161 stock market capitalisation.
| Year | Reinvestment Ratio | Operating CF (TWD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.38x | NT$59.99 Million | NT$22.80 Million | ▲ +289.4% |
| 2024 | 0.10x | NT$158.82 Million | NT$15.51 Million | ▼ -35.2% |
| 2023 | 0.15x | NT$205.95 Million | NT$31.04 Million | ▼ -51.4% |
| 2022 | 0.31x | NT$55.06 Million | NT$17.08 Million | ▼ -84.5% |
| 2020 | 2.01x | NT$6.57 Million | NT$13.18 Million | ▲ +200.0% |
| 2019 | 0.67x | NT$41.03 Million | NT$27.42 Million | ▼ -45.1% |
| 2018 | 1.22x | NT$41.83 Million | NT$50.96 Million | ▼ -78.6% |
| 2017 | 5.69x | NT$11.02 Million | NT$62.72 Million | — |